期刊文献+

白细胞介素37与冠心病的关系及相关研究进展 被引量:3

Relationship between Interleukin-37 and Coronary Heart Disease and the Related Research Progress
下载PDF
导出
摘要 冠心病的主要病理生理基础是动脉粥样硬化。动脉粥样硬化实际上是一种慢性炎症性疾病,在疾病过程中,各种炎性细胞及炎性因子均发挥了重要作用。其中白细胞介素37作为一种新型抗炎因子,可以通过抑制促炎因子的生成等多种途径影响冠心病的疾病进程。研究炎症反应机制和相关炎性因子有望为明确冠心病的病因及进一步的预防和治疗开辟新的途径。 It is well known that atherosclerosis is the pathophysiological basis of coronary heart disease(CHD). Athero-sclerosis is actually an inflammatory disorder, and lots of inflammatory cells and inflammatory cytokines play important rolesin this process. Interleukin-37, a newly found anti-inflammatory cytokine, is involved in the process of CHD by multiplemechanisms like inhibiting production of proinflammatory factors and so on. The research of the inflammatory reaction mech-anism and the related inflammatory cytokines will open a new way to clarify the etiology and further the prevention as well asthe treatment of CHD.
作者 沈忱 杨超
出处 《医学综述》 2017年第7期1254-1257,1262,共5页 Medical Recapitulate
基金 深圳市科技计划项目(深科技创新[2016]148号)
关键词 冠心病 动脉粥样硬化 炎症 抗炎因子 白细胞介素37 Coronary heart disease Atherosclerosis Inflammation Anti-inflammatory factors Interleukin-37
  • 相关文献

参考文献4

二级参考文献63

  • 1张占海.CTFC对冠脉直接支架置入术后血流评价作用[J].郑州大学学报(医学版),2005,40(5):934-935. 被引量:4
  • 2胡盛寿,孔灵芝.中国心血管病报告[R].中国大百科全书出版社,2011.3:13-6.
  • 3Diana Boraschi, Davide Lucchesi, Stefan Hainzl,et al. IL-37: a new anti-inflammatory cytokine of the IL-1 family[J]. European Cytokine Network,2011,22:127-47.
  • 4Kumar S,McDommell PC,Lehr R,et al. Identification and initial characterization of four novel members of the interleukin-1 family[J]. Biol Chem,2000,275(14):10308-14.
  • 5Dohi T, Miyauchi K,Okazaki S,et al. Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): a follow-up study[J]. Atherosclerosis,2010,210(2): 497-502.
  • 6Patti G,Chello M,Gatto L,et al. Short-term atorvastatin preload reduces levels of adhesion molecules in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Results from the ARMYDA-ACS CAMs (Atorvastatin for Reduction ofmyocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy[J]. Cardiovasc Med (Hagerstown) 2010,11(11):795-800.
  • 7Pasceri V,Patti G,Nusca A,et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (atorvastatin for reduction of myocardial Damage during Angioplasty) study[J]. Circulation,2004,110(6):674-8.
  • 8Liu P,Jiang J,Li J,et al. Intensive statin therapy for Chinese patients with coronary artery disease undergoing percutaneous coronary intervention (ISCAP study): rationale and design[J]. Catheter Cardiovasc Interv,2012,79(6):967-71.
  • 9Ge J,Kim YJ,Jang YS,et al. Design and rationale of a study in Asia of atorvastatin pretreatment in patients undergoing percutaneous coronary intervention for non-STelevation acute coronary syndromes[J]. J Cardiol,2010,55(3):303-8.
  • 10Bulau AM,Fink M,Maucksch C,et al. In Vivo Expression of interleukin-37 reduces local and systemic inflammation in concanavalin A-induced hepatitis[J]. Scientific,World Journal,2011, 11:2480-90.

共引文献14

同被引文献12

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部